Actively Recruiting
Phase 3 Extension Study of siRNA Targeting Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
Led by ADARx Pharmaceuticals, Inc. · Updated on 2026-04-30
90
Participants Needed
48
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research focuses on participants with Type I and Type II hereditary angioedema (HAE) who have completed the Phase 3 ADX-324-301 trial. It aims to gather more information about the safety and effectiveness of additional doses of ADX-324, a treatment being studied for HAE. The study also evaluates how the drug affects the body, including pharmacodynamic and pharmacokinetic responses, as well as participants' quality of life. Participants will receive one of two doses of ADX-324, a siRNA duplex oligonucleotide. This extension study follows the previous trial and continues to monitor participants over an extended period to assess the ongoing impact of the treatment. The study is double-blinded and non-randomized, meaning participants and researchers do not know which dose is given, and all participants receive the study drug. During the study, participants will undergo safety monitoring up to 36 months to track any side effects or adverse reactions. Researchers will also measure the effectiveness of ADX-324 in preventing HAE attacks over the same time frame. Participants will be evaluated regularly for drug effects, health status, and quality of life changes as part of their involvement in this extended follow-up trial.
CONDITIONS
Brief Title
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have a documented diagnosis of HAE (Type I or II)
- Completed Study ADX-324-301
- Have access to an acute therapy to treat HAE attacks such as plasma derived or recombinant C1-INH concentrate or a BK2-receptor antagonist
You will not qualify if you...
- Had a negative reaction to the study drug in ADX-324-301
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 36 months
Participants receive ADX-324 at one of two dose levels as an active treatment for hereditary angioedema.
Trial Site Locations
Total: 48 locations
1
ADARx Clinical Site
Litchfield Park, Arizona, United States, 85340
Not Yet Recruiting
2
ADARx Clinical Site
Little Rock, Arkansas, United States, 72205
Not Yet Recruiting
3
ADARx Clinical Site
San Diego, California, United States, 92122
Not Yet Recruiting
4
ADARx Clinical Site
Walnut Creek, California, United States, 94598
Not Yet Recruiting
5
ADARx Clinical Site
Orlando, Florida, United States, 32807
Not Yet Recruiting
6
ADARx Clinical Site
Chevy Chase, Maryland, United States, 20815
Not Yet Recruiting
7
ADARx Clinical Site
Wheaton, Maryland, United States, 20902
Not Yet Recruiting
8
ADARx Clinical Site
Detroit, Michigan, United States, 48202
Not Yet Recruiting
9
ADARx Clinical Site
St Louis, Missouri, United States, 63141
Not Yet Recruiting
10
ADARx Clinical Site
Las Vegas, Nevada, United States, 89128
Actively Recruiting
11
ADARx Clinical Site
New York, New York, United States, 10029
Not Yet Recruiting
12
ADARx Clinical Site
Cincinnati, Ohio, United States, 45236
Not Yet Recruiting
13
ADARx Clinical Site
Columbus, Ohio, United States, 43235
Not Yet Recruiting
14
ADARx Clinical Site
Toledo, Ohio, United States, 43617
Not Yet Recruiting
15
ADARx Clinical Site
Hershey, Pennsylvania, United States, 17033
Not Yet Recruiting
16
ADARx Clinical Site
Capital Federal, Buenos Aires, Argentina, C1425BEN
Not Yet Recruiting
17
ADARx Clinical Site
Buenos Aires, Buenos Aires F.D., Argentina, C1035AAT
Not Yet Recruiting
18
ADARx Clinical Site
Adelaide, South Australia, Australia, 5000
Not Yet Recruiting
19
ADARx Clinical Site
Vienna, Austria, 1090
Not Yet Recruiting
20
ADARx Clinical Site
Edegem, Antwerpen, Belgium, 2650
Not Yet Recruiting
21
ADARx Clinical Site
Sofia, Bulgaria, 1000
Not Yet Recruiting
22
ADARx Clinical Site
Edmonton, Alberta, Canada, T6G 2R3
Not Yet Recruiting
23
ADARx Clinical Site
Ottawa, Ontario, Canada, K1H 1E4
Not Yet Recruiting
24
ADARx Clinical Site
Montreal, Quebec, Canada, H2W 1R7
Not Yet Recruiting
25
ADARx Clinical Site
Beijing, China, 100730
Not Yet Recruiting
26
ADARx Clinical Site
Harbin, China, 150001
Not Yet Recruiting
27
ADARx Clinical Site
Zhengzhou, China, 450003
Not Yet Recruiting
28
ADARx Clinical Site
Split, Croatia, 21000
Not Yet Recruiting
29
ADARx Clinical Site
Zagreb, Croatia, 10000
Not Yet Recruiting
30
ADARx Clinical Site
Hradec Králové, Czechia, 500 05
Not Yet Recruiting
31
ADARx Clinical Site
Prague, Czechia, 15000
Not Yet Recruiting
32
ADARx Clinical Site
Nice, Alpes-Maritimes, France, 06300
Not Yet Recruiting
33
ADARx Clinical Site
Tours, Indre-et-Loire, France, 37000
Not Yet Recruiting
34
ADARx Clinical Site
Montpellier, France, 34295
Not Yet Recruiting
35
ADARx Clinical Site
Paris, France, 75012
Not Yet Recruiting
36
ADARx Clinical Site
Tübingen, Baden-Wurttemberg, Germany, 72076
Not Yet Recruiting
37
ADARx Clinical Site
Hong Kong, Hong Kong, 111
Not Yet Recruiting
38
ADARx Clinical Site
Budapest, Hungary, 1088
Not Yet Recruiting
39
ADARx Clinical Site
Ashkelon, Israel, 7830604
Not Yet Recruiting
40
ADARx Clinical Site
Tel Aviv, Israel, 5262100
Not Yet Recruiting
41
ADARx Clinical Site
Lodz, Poland, 92-213
Not Yet Recruiting
42
ADARx Clinical Site
Barcelona, Spain, 08907
Not Yet Recruiting
43
ADARx Clinical Site
Madrid, Spain, 28007
Not Yet Recruiting
44
ADARx Clinical Site
Taichung, Taiwan, 40705
Not Yet Recruiting
45
ADARx Clinical Site
Cambridge, United Kingdom, CB2 0QQ
Not Yet Recruiting
46
ADARx Clinical Site
Cardiff, United Kingdom, CF14 4YS
Not Yet Recruiting
47
ADARx Clinical Site
London, United Kingdom, E1 1BB
Not Yet Recruiting
48
ADARx Clinical Site
Southampton, United Kingdom, SO16 6YD
Not Yet Recruiting
Research Team
L
Lupe Gallegos
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here